Form 10-Q NANOVIRICIDES, INC. For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
NanoViricides (NNVC) Reports Q2 Loss of $0.04/Share
February 25, 2015 9:21 AM ESTNanoViricides (AMEX: NNVC) reported Q2 EPS of ($0.04), versus ($0.03) reported last year. Revenue for the quarter came in at $1.82 million, versus $1.75 million reported last year.
The Company estimates that it now has approximately $36.4 Million (M) of current assets plus restricted cash (cash, cash equivalents, collateral advance, prepaid expenses, and security deposits) as of December 31, 2014, the end of the reporting quarter. The Company's operating expenditure during this quarter was approximately $1.9M. Shareholder equity stood at approximately $30.5M for the quarter.
The Company reports that all of its drug development programs are progressing... More



